Assessing genetic markers of tumour progression in the context of intratumour heterogeneity

Cytometry

Volumn 31, Issue 1, 1998, Pages 67-73

  Chapman, Judith Anne W ^a   Wolman, Eric ^b   Wolman, Sandra R ^c   Remvikos, Yorghos ^d   Shackney, Stanley ^e   Axelrod, David E ^f   Baisch, Heinz ^g   Christensen, Ib Jarle ^h   White, R Allen ⁱ   Liebovitch, Larry S ^j   Moore, Dan H ^k   Waldman, Frederic M ^l   Cornelisse, Cees J ^m   Shankey, T Vincent ⁿ  

^a UNIVERSITY OF TORONTO   (Canada)

^b George Mason University   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d CNRS   (France)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f RUTGERS UNIVERSITY   (United States)

^g UNIVERSITY OF HAMBURG   (Germany)

^h FINSEN LABORATORY   (Denmark)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j FLORIDA ATLANTIC UNIVERSITY   (United States)

^k CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Genetic markers; Intratumour heterogeneity; Tumour progression

Indexed keywords

ARTICLE; CANCER GENETICS; CELL HETEROGENEITY; GENETIC MARKER; HUMAN; HYPOTHESIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL MODEL; TUMOR GROWTH;

DISEASE PROGRESSION; EVALUATION STUDIES; GENETIC HETEROGENEITY; GENETIC MARKERS; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 15144357001     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19980101)31:1<67::AID-CYTO9>3.0.CO;2-G     Document Type: Article

References (28)

1. Baisch H, Otto U. Intratumoural heterogeneity of S-phase transition in solid tumours determined by bromodeoxyuridine labelling and flow cytometry. Cell Prolif 26:439-448, 1993.
2. Baisch H, Otto U, Hatje U, Fack H. Heterogeneous cell kinetics in tumors analyzed with a simulation model for bromodeoxyuridine single and multiple labeling. Cytometry 21:52-61, 1995.
3. Bassingthwaighte JB, Liebovitch LS, West BS. Fractal Physiology. New York, Oxford University Press, 1994.
4. Beerman H, Smit VTHBM, Kluin PM, Bonsing BA, Hermans J, Cornelisse CJ. Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12:147-154, 1991.
5. Bergers E, van Diest PJ, Baak JP. Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 49:931-937, 1996.
6. Box GEP, Cox DR. Analysis of Transformations. J R Stat Soc Ser B 26:211-252, 1964.
7. Chapman JW, Mobbs BG, Hanna WM, Sawka CA, Pritchard KI, Lickley HLA, Trudeau ME, Ryan ED, Ooi TC, Sutherland DJA, Tustanoff ER, McCready DR. The standardization of estrogen receptors. J Steroid Biochem Mol Biol 45:367-373, 1993.
8. Chapman JW, Mobbs BG, McCready DR, Lickley HLA, Trudeau ME, Hanna W, Kahn HJ, Sawka CA, Fish EB, Pritchard KI. An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. J Steroid Biochem Mol Biol 57:323-328, 1996.
9. Chapman JW, Murray D, McCready DR, Hanna W, Kahn HJ, Lickley HLA, Trudeau ME, Mobbs BG, Sawka CA, Fish EB, Pritchard KI. An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer? Eur J Cancer 32A:1949-1956, 1996.
10. Dodd LJ, Kerns BJ, Dodge RK, Layfield LJ. Intratumoral heterogeneity in primary breast carcinoma: study of concurrent parameters. J Surg Oncol 64:280-287, 1997 (discussion 287-288).
11. Fujimaki E, Sasaki K, Nakano O, Chiba S, Tazawa H, Yamashiki H, Orii S, Sugai T. DNA ploidy heterogeneity in early and advanced gastric cancers. Cytometry 26:131-136, 1996.
12. Hanna W, McCready DR, Chapman JW, Mobbs BG, Trudeau ME. The predictive value of ERICA in breast cancer recurrence: A univariate and multivariate analysis. Mod Pathol 6:748-754, 1993.
13. Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR. Extensive genetic alterations in prostate cancer relealed by dual PCR and FISH analysis. Genes Chromosomes Cancer 8:88-97, 1993.
14. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
15. 1/S boundary after irradiation. Oncogene 12:875-882, 1996.
16. Prognostic factor integration. Editor GM Clark. Special issue Breast Cancer Res Treat 22:185-293, 1992.
17. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H and Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: A flow cytometry study on fine needle aspirates. Eur J Cancer 29A:1843-1848, 1993.
18. Rosenberg P, Wingren S, Guerrieri C. Flow cytometric DNA-heterogeneity in paraffin-embedded endometrial cancer. Acta Oncol 36:23-26, 1997.
19. Ryan ED, Clark AF, Mobbs BG, Ooi TC, Sutherland DJA, Tustanoff ER. Interlaboratory quality control of estrogen and progesterone receptor assays in breast cancer tissue using lyophilised cytosols. Clin Biochem 18:20-26, 1985.
20. Spratt JS. The lognormal frequency distribution and human cancer. J Surg Res 9:151-157, 1969.
21. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms. Part I. J Surg Oncol 60:137-146, 1995.
22. Tollenaar RA, Bonsing BA, Kuipers-Dijkshoorn NJ, Hermans J, van de Velde CJ, Cornelisse CJ, Fleuren GJ. Evidence of clonal divergence in colorectal carcinoma. Cancer 79:1304-1314, 1997.
23. Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105:607-612, 1993.
24. White RA, Terry NHA, Baggerly KA, Meistrich ML. Measuring cell proliferation by relative movement. I. Introduction and in vitro studies. Cell Prolif 24:257-270, 1991.
25. Wilson GD, McNally NJ, Dische S, Saunders I, Des Rochers C, Lewis AA, Bennett MH. Measurement of cell kinetics in human tumours in vitro using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 58:423-431, 1988.
26. Wolman SR, Macoska JA, Micale MA, Sakr WA. An approach to definition of genetic alterations in prostate cancer. Diagn Mol Pathol 1:192-199, 1992.
27. Wolman SR, Sanford J, Ratner S, Dawson PJ: Breast cancer in males: DNA content and sex chromosome constitution. Mod Pathol 8:239-243, 1995.
28. Wolman SR, Waldman FM, Balazs M. Complementarity of interphase and metaphase chromosome analysis in human renal tumours. Genes Chromosomes Cancer 6:17-23, 1993.